MediWound Business Summary

MediWound Ltd. (MDWD) is a commercial-stage biopharmaceutical company specializing in enzymatic, non-surgical therapies for tissue repair and regeneration. The company generates revenue through a multi-pronged model comprising direct product sales of its flagship biologic, NexoBrid, and extensive non-dilutive funding from U.S. government contracts with BARDA and the Department of Defense. Additionally, MediWound utilizes a licensing and royalty model, partnering with Vericel Corporation for North American commercialization and Kaken Pharmaceutical in Japan. The business is segmented into acute burn care, centered on the FDA-approved NexoBrid for eschar removal, and chronic wound care, led by the Phase III candidate EscharEx for venous leg ulcers. Primary competitors include Smith & Nephew (specifically its Santyl ointment), SanuWave Health, and Tissue Regenix. MediWound occupies a unique market niche as the leader in selective enzymatic debridement, offering a rapid, bedside alternative to surgical excision that preserves healthy tissue and reduces healthcare costs. The leadership team is headed by CEO Ofer Gonen, who brings over 20 years of executive experience from Clal Biotechnology Industries and the Anatomy Medical Technology Fund. Key executives include CFO Hani Luxenburg, a veteran in life sciences financial leadership, and COO & Chief Commercial Officer Dr. Shmulik Hess, who previously served as CEO of Enlivex Therapeutics. Clinical strategy is overseen by Chief Medical Officer Dr. Ety Klinger, a former R&D leader at Teva Pharmaceuticals. The company was founded by Professor Lior Rosenberg, a renowned plastic surgeon who remains a pivotal medical director. The Board of Directors is chaired by Nachum (Homi) Shamir, former CEO of Luminex Corporation, and includes Stephen T. Wills, CFO of Palatin Technologies. Notable institutional backers include Yelin Lapidot Holdings, Point72 Asset Management, and Rosalind Advisors.